AmericasENPublic regulatory overview
Argentina
Market Overview Population: Approximately 46 million (2024), South America's secondlargest economy Healthcare system: Threetier structure — public hospitals (managed by MINSAL, fre...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRModerate benefitCE evidence provides a strong technical-file template but does not replace the local review.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Argentina
- Product line: Medical devices
- Regulator / source: Regulatory maturity: Moderate — ANMAT's framework is relatively comprehensive and references GHTF/EU principles. However, reviewer resources are limited and administrative efficiency is affected by the macroeconomic environment. Review timelines are unpredictable during economic crises
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulatory maturity: Moderate — ANMAT's framework is relatively comprehensive and references GHTF/EU principles. However, reviewer resources are limited and administrative efficiency is affected by the macroeconomic environment. Review timelines are unpredictable during economic crises
- Key fees: Market characteristics: The medical device market is valued at approximately USD 2–3 billion per year (figures are highly volatile in USD terms due to FX conditions). Import dependency is approximately 70–80%. Domestic manufacturing is active in consumables, medical furniture, and basic equipment. Severe macroeconomic instability — inflation exceeding 200% in 2023, FX controls, and recurring economic crises — represents the single greatest market risk. The Milei government (in office since late 2023) is pursuing economic liberalization; FX controls have been partially relaxed but remain in place
- Local requirement: Disposición ANMAT 2319/2002 (importer certification)
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 46 million (2024), South America's second-largest economy
- Healthcare system: Three-tier structure — public hospitals (managed by MINSAL, free of charge); Obras Sociales (social insurance funds organized by sector and trade union, covering approximately 50% of the population); PAMI (healthcare for retirees, covering approximately 5 million pensioners); and private Prepagas/Mutuales (private health insurance for middle- and upper-income groups)
- Market characteristics: The medical device market is valued at approximately USD 2–3 billion per year (figures are highly volatile in USD terms due to FX conditions). Import dependency is approximately 70–80%. Domestic manufacturing is active in consumables, medical furniture, and basic equipment. Severe macroeconomic instability — inflation exceeding 200% in 2023, FX controls, and recurring economic crises — represents the single greatest market risk. The Milei government (in office since late 2023) is pursuing economic liberalization; FX controls have been partially relaxed but remain in place
- Regulatory maturity: Moderate — ANMAT's framework is relatively comprehensive and references GHTF/EU principles. However, reviewer resources are limited and administrative efficiency is affected by the macroeconomic environment. Review timelines are unpredictable during economic crises
Regulatory Authority
- Primary authority: ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), under the Ministerio de Salud de la Nación
- Official portal: https://www.argentina.gob.ar/anmat; electronic filing system: ECAS (Expediente Electrónico para Autorización Sanitaria); SNIMED (Sistema Nacional de Información en Medicamentos y Tecnologías)
- Key regulations:
- Ley 16.463/1964 (basic law on pharmaceuticals and medical devices)
- Decreto 150/1992 (pharmaceutical regulatory framework)
- Disposición ANMAT 2318/2002 (medical device registration regulations)
- Disposición ANMAT 4537/1998 (medical device classification)
- Disposición ANMAT 2319/2002 (importer certification)
- Disposición ANMAT 4980/2005 (technical review requirements)
- Disposición 6248/2012 (post-market surveillance / vigilance)
- Annual Disposiciones and updates
Device Classification
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Clase I | Low risk | EU Class I / FDA Class I | Simplified registration or notification only |
| Clase II | Low-moderate risk | EU Class IIa / FDA Class II | Certificado de Registro; standard review |
| Clase III | Moderate-high risk | EU Class IIb / FDA Class II-III | Certificado de Registro; more stringent review |
| Clase IV | High risk | EU Class III / FDA Class III | Certificado de Registro; most stringent review |
Note: Classification is governed by Disposición 4537/1998; the Argentine four-class system corresponds relatively directly to the EU four-tier framework. Classification inquiries may be submitted to ANMAT.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.